Plain-English translation of NCT04053855 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Researchers are studying tiny particles called exosomes that are shed into urine by kidney cancer cells. This trial aims to see whether detecting specific markers on these exosomes in a urine sample could help identify clear cell renal cell carcinoma — the most common type of kidney cancer. If successful, this could become a simple, non-invasive test to help diagnose kidney cancer.
Currently, kidney cancer is often found by accident on imaging tests done for other reasons, or when symptoms appear late. Doctors need better, simpler ways to detect kidney cancer earlier. This study is exploring whether analyzing urine samples could provide an easy screening tool.
You likely qualify if…
You likely don't qualify if…
If you qualify, you will be asked to provide a urine sample, which researchers will then analyze under a microscope to look for the markers associated with kidney cancer. The study compares samples from patients with kidney masses requiring surgery to samples from healthy volunteers without kidney masses, helping researchers understand whether this test could reliably detect cancer.
AI-generated summary from trial data · Jul 6, 2026 · Not medical advice
France
Enrollment target
~100 participants
Started
January 2020
Primary completion
August 2026
Age range
18 Years and older
Last updated on clinicaltrials.gov in May 2026.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Nicolas MOTTET, MD PhD
Centre Hospitalier Universitaire de Saint Etienne
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.